Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

Background. Palivizumab is a US Food and Drug Administration–approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with enhanced antiviral activity, has recently been tested in humans...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zhu, Qing, McAuliffe, Josie M., Patel, Nita K., Palmer-Hill, Frances J., Yang, Chin-fen, Liang, Brandon, Su, Lan, Zhu, Wei, Wachter, Leslie, Wilson, Susan, MacGill, Randall S., Krishnan, Subramaniam, McCarthy, Michael P., Losonsky, Genevieve A., Suzich, JoAnn A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2011
Schlagworte:
Major Articles and Brief Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3072724/
https://ncbi.nlm.nih.gov/pubmed/21208913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiq100
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge